董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen Oesterle | 男 | Director | 69 | 未披露 | 未持股 | 2020-09-30 |
| James Gilbert | 男 | Director | 62 | 未披露 | 未持股 | 2020-09-30 |
| Kavita Patel | 女 | Director | 46 | 未披露 | 未持股 | 2020-09-30 |
| Daniel G. Anderson | 男 | Director | 51 | 15.00万美元 | 未持股 | 2020-09-30 |
| John Cox | 男 | Director | 58 | 16.08万美元 | 未持股 | 2020-09-30 |
| Robert Langer | -- | Director | 72 | 未披露 | 未持股 | 2020-09-30 |
| Robert Ruffolo, Jr. | 男 | Director | 70 | 未披露 | 未持股 | 2020-09-30 |
| Eric Shaff | 男 | Director | 44 | 未披露 | 未持股 | 2020-09-30 |
| Douglas Cole | 男 | Chairman | 60 | 未披露 | 未持股 | 2020-09-30 |
| Rogerio Vivaldi Coelho | 男 | President & Chief Executive Officer, Director | 56 | 72.32万美元 | 未持股 | 2020-09-30 |
| Robert Langer | 男 | Director | 72 | 15.00万美元 | 未持股 | 2020-09-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Deya Corzo | 女 | Chief Medical Officer | 54 | 未披露 | 未持股 | 2020-09-30 |
| Glenn Reicin | 男 | Chief Financial Officer and Treasurer | 56 | 91.46万美元 | 未持股 | 2020-09-30 |
| Devyn Smith | 男 | Chief Operating Officer | 49 | 68.27万美元 | 未持股 | 2020-09-30 |
| Rogerio Vivaldi Coelho | 男 | President & Chief Executive Officer, Director | 56 | 72.32万美元 | 未持股 | 2020-09-30 |
董事简历
中英对照 | 中文 | 英文- Stephen Oesterle
-
Stephen Oesterle，他于2016年1月加入Paragon 28, Inc.董事会。他是全球风险投资公司New Enterprise Associates, Inc. NEA的投资合伙人，从事NEA的医疗设备投资实践。加入NEA之前，他担任Medtronic, Inc.的医学和技术高级副总裁以及执行委员会成员。他在此为Medtronic科学研究、技术策略和发展关系提供医疗社区、技术大学、金融机构和世界各地的新兴医疗器械公司的执行领导。2002年加入Medtronic之前，他担任the Harvard University Medical School的医学副教授和波士顿Massachusetts General Hospital的侵入性心脏病学服务的主任。他在Good Samaritan Hospital（从1986年到1991年）、Georgetown University（从1991年到1992年）和Stanford University（从1992年到1998年）发展和领导介入性心脏病学项目。他以优异的成绩毕业于Harvard。他获得Yale University School of Medicine的医学学位。
Stephen Oesterle has served as a member of our board of directors since January 2021 and has served as our lead director since October 2021. He is a consultant, advising private equity and operating companies in the healthcare industry. From January 2002 to November 2015 he was a member of the Executive Committee of Medtronic plc, serving as Senior Vice President of Medicine and Technology. Previously, he served as an Associate Professor of Medicine and Director of Invasive Cardiology Services at each of Massachusetts General Hospital 1998 to 2002 Stanford University Medical Center (1992 to 1998) and Georgetown University Medical Center (1991 to 1992). Dr. Oesterle has served as director of Sigilon Therapeutics, Inc. (Nasdaq: "SGTX"), as therapeutics company, since 2016 and Baxter International Inc. (NYSE: "BAX"), a multinational healthcare company, since 2017. Dr. Oesterle has also served as an advisor to Temasek Holdings LTD and EQT Partners since 2015. He previously served as a director of REVA Medical, Inc. from February 2018 to May 2019 and of HeartWare International, Inc. (HeartWare) from January 2016 to November 2016 prior to Medtronic's acquisition on of HeartWare. Dr. Oesterle is a summa cum laude graduate of Harvard College and received his medical doctorate from Yale University. - Stephen Oesterle，他于2016年1月加入Paragon 28, Inc.董事会。他是全球风险投资公司New Enterprise Associates, Inc. NEA的投资合伙人，从事NEA的医疗设备投资实践。加入NEA之前，他担任Medtronic, Inc.的医学和技术高级副总裁以及执行委员会成员。他在此为Medtronic科学研究、技术策略和发展关系提供医疗社区、技术大学、金融机构和世界各地的新兴医疗器械公司的执行领导。2002年加入Medtronic之前，他担任the Harvard University Medical School的医学副教授和波士顿Massachusetts General Hospital的侵入性心脏病学服务的主任。他在Good Samaritan Hospital（从1986年到1991年）、Georgetown University（从1991年到1992年）和Stanford University（从1992年到1998年）发展和领导介入性心脏病学项目。他以优异的成绩毕业于Harvard。他获得Yale University School of Medicine的医学学位。
- Stephen Oesterle has served as a member of our board of directors since January 2021 and has served as our lead director since October 2021. He is a consultant, advising private equity and operating companies in the healthcare industry. From January 2002 to November 2015 he was a member of the Executive Committee of Medtronic plc, serving as Senior Vice President of Medicine and Technology. Previously, he served as an Associate Professor of Medicine and Director of Invasive Cardiology Services at each of Massachusetts General Hospital 1998 to 2002 Stanford University Medical Center (1992 to 1998) and Georgetown University Medical Center (1991 to 1992). Dr. Oesterle has served as director of Sigilon Therapeutics, Inc. (Nasdaq: "SGTX"), as therapeutics company, since 2016 and Baxter International Inc. (NYSE: "BAX"), a multinational healthcare company, since 2017. Dr. Oesterle has also served as an advisor to Temasek Holdings LTD and EQT Partners since 2015. He previously served as a director of REVA Medical, Inc. from February 2018 to May 2019 and of HeartWare International, Inc. (HeartWare) from January 2016 to November 2016 prior to Medtronic's acquisition on of HeartWare. Dr. Oesterle is a summa cum laude graduate of Harvard College and received his medical doctorate from Yale University.
- James Gilbert
-
James Gilbert自2017年6月以来一直担任我们的董事会成员。Gilbert先生是旗舰先锋公司（Flagship Pioneural）的高级合伙人。在2016年加入Flagship Pioneur，Inc.之前，吉尔伯特先生曾担任投资公司General Atlantic的高级顾问，并担任Welsh，Carson，Anderson&Stowe的高级运营执行官。Gilbert先生从2004年到2010年担任波士顿科学国际有限公司公司企业战略和BD的执行Vice President和心血管集团总裁，从1981年到2004年担任合伙人，包括担任贝恩公司（Bain&Company）全球梦百合业务总经理和管理委员会主席。除了我们的董事会，Gilbert先生也是National Dentex Corporation的董事会成员。他曾任职于ECG管理顾问公司、KSQ治疗公司、金泰治疗公司、雀巢健康科学公司、RubiusTherapeutics，Inc.和TransMedics公司的董事会。Gilbert先生拥有康奈尔大学（Cornell University）的学士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
James Gilbert has served as a member of our board of directors since June 2017. Mr. Gilbert is a senior partner of Flagship Pioneering. Before joining Flagship Pioneering, Inc. in 2016 Mr. Gilbert served as a senior advisor to the investment firm General Atlantic and as a senior operating executive at Welsh, Carson, Anderson & Stowe. From 2004-2010 Mr. Gilbert was an Executive Vice President of Corporate Strategy and BD, and Cardiovascular Group President at Boston Scientific Corporation and from 1981-2004 a Partner, including serving as the Managing Director of the Global Healthcare Practice and Chairman of the Management Committee at Bain & Company. In addition to our board, Mr. Gilbert is also a board member of National Dentex Corporation. He previously served on the boards of directors of ECG Management Consultants, Inc., KSQ Therapeutics, Inc., Kintai Therapeutics, Inc., Nestlé Health Science S.A., Rubius Therapeutics, Inc. and TransMedics, Inc. Mr. Gilbert has a B.S. from Cornell University and an M.B.A. from Harvard Business School. - James Gilbert自2017年6月以来一直担任我们的董事会成员。Gilbert先生是旗舰先锋公司（Flagship Pioneural）的高级合伙人。在2016年加入Flagship Pioneur，Inc.之前，吉尔伯特先生曾担任投资公司General Atlantic的高级顾问，并担任Welsh，Carson，Anderson&Stowe的高级运营执行官。Gilbert先生从2004年到2010年担任波士顿科学国际有限公司公司企业战略和BD的执行Vice President和心血管集团总裁，从1981年到2004年担任合伙人，包括担任贝恩公司（Bain&Company）全球梦百合业务总经理和管理委员会主席。除了我们的董事会，Gilbert先生也是National Dentex Corporation的董事会成员。他曾任职于ECG管理顾问公司、KSQ治疗公司、金泰治疗公司、雀巢健康科学公司、RubiusTherapeutics，Inc.和TransMedics公司的董事会。Gilbert先生拥有康奈尔大学（Cornell University）的学士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
- James Gilbert has served as a member of our board of directors since June 2017. Mr. Gilbert is a senior partner of Flagship Pioneering. Before joining Flagship Pioneering, Inc. in 2016 Mr. Gilbert served as a senior advisor to the investment firm General Atlantic and as a senior operating executive at Welsh, Carson, Anderson & Stowe. From 2004-2010 Mr. Gilbert was an Executive Vice President of Corporate Strategy and BD, and Cardiovascular Group President at Boston Scientific Corporation and from 1981-2004 a Partner, including serving as the Managing Director of the Global Healthcare Practice and Chairman of the Management Committee at Bain & Company. In addition to our board, Mr. Gilbert is also a board member of National Dentex Corporation. He previously served on the boards of directors of ECG Management Consultants, Inc., KSQ Therapeutics, Inc., Kintai Therapeutics, Inc., Nestlé Health Science S.A., Rubius Therapeutics, Inc. and TransMedics, Inc. Mr. Gilbert has a B.S. from Cornell University and an M.B.A. from Harvard Business School.
- Kavita Patel
-
Kavita Patel自2020年以来一直担任我们的董事会成员。Kavita Patel博士是华盛顿特区的执业医师，也是布鲁金斯学会（Brookings Institution）的非居民研究员，在那里她的研究和报告专注于以患者为中心的护理，支付和交付系统以及医疗改革。她此前曾任职奥巴马政府，担任白宫政府间事务和公众参与办公室的政策主管。她还曾担任已故参议员Edward Kennedy的政策分析师和助手。作为卫生部副部长，她是肯尼迪参议员领导下的卫生、教育、劳工和养老金帮助委员会的高级职员的一部分。Patel博士还担任布鲁金斯学会卫生政策中心临床转化的常务董事和约翰霍普金斯卫生系统付款人和提供者战略的Vice President。Patel博士目前在SelectQuote，Inc.公司董事会任职。Patel博士在几个非营利组织的董事会任职，包括Dignity梦百合和SSM梦百合。她在德克萨斯大学健康科学中心获得医学博士学位，在加州大学洛杉矶分校获得医学硕士学位。
Kavita Patel,was appointed to serve as a director of the Company in September 2020. Dr. Patel is also a practicing primary care physician at Mary's Center in Washington, D.C. and has served as a Venture Partner at New Enterprise Associates since 2017. From 2011–2021, she was a managing director of health care delivery and transformation at the Brookings Institution. She also previously served as Director of Policy for the Office of Intergovernmental Affairs and Public Engagement in the White House from 2009 to 2010, as Deputy Staff Director on Health on the late Senator Edward Kennedy's staff from 2007 to 2009, and as a member of senior staff of the Senate Health, Education, Labor and Pensions (HELP) Committee. Dr. Patel has served as a director and member of the Compensation Committee of Arcellx, Inc. (NASDAQ: ACLX) since December 2021. She previously served as a director and member of the Compensation Committee of Sigilon Therapeutics, Inc. (NASDAQ: SGTX) from April 2020 until its sale to Eli Lilly and Company in August 2023; as a director and member of the Governance and Nominating Committee of Tesaro, Inc. (NASDAQ: TSRO) from 2016 until its acquisition by GlaxoSmithKline in 2019; and as a director, member of the Compensation Committee, and Chair of the Nominating and Corporate Governance Committee of Intelligent Medicine Acquisition Corp (NASDAQ: IQMD) from November 2021 to April 2023. Dr. Patel received her undergraduate degree from the University of Texas at Austin, her Master of Public Health from the University of California at Los Angeles and her medical degree from the University of Texas Health Science Center. - Kavita Patel自2020年以来一直担任我们的董事会成员。Kavita Patel博士是华盛顿特区的执业医师，也是布鲁金斯学会（Brookings Institution）的非居民研究员，在那里她的研究和报告专注于以患者为中心的护理，支付和交付系统以及医疗改革。她此前曾任职奥巴马政府，担任白宫政府间事务和公众参与办公室的政策主管。她还曾担任已故参议员Edward Kennedy的政策分析师和助手。作为卫生部副部长，她是肯尼迪参议员领导下的卫生、教育、劳工和养老金帮助委员会的高级职员的一部分。Patel博士还担任布鲁金斯学会卫生政策中心临床转化的常务董事和约翰霍普金斯卫生系统付款人和提供者战略的Vice President。Patel博士目前在SelectQuote，Inc.公司董事会任职。Patel博士在几个非营利组织的董事会任职，包括Dignity梦百合和SSM梦百合。她在德克萨斯大学健康科学中心获得医学博士学位，在加州大学洛杉矶分校获得医学硕士学位。
- Kavita Patel,was appointed to serve as a director of the Company in September 2020. Dr. Patel is also a practicing primary care physician at Mary's Center in Washington, D.C. and has served as a Venture Partner at New Enterprise Associates since 2017. From 2011–2021, she was a managing director of health care delivery and transformation at the Brookings Institution. She also previously served as Director of Policy for the Office of Intergovernmental Affairs and Public Engagement in the White House from 2009 to 2010, as Deputy Staff Director on Health on the late Senator Edward Kennedy's staff from 2007 to 2009, and as a member of senior staff of the Senate Health, Education, Labor and Pensions (HELP) Committee. Dr. Patel has served as a director and member of the Compensation Committee of Arcellx, Inc. (NASDAQ: ACLX) since December 2021. She previously served as a director and member of the Compensation Committee of Sigilon Therapeutics, Inc. (NASDAQ: SGTX) from April 2020 until its sale to Eli Lilly and Company in August 2023; as a director and member of the Governance and Nominating Committee of Tesaro, Inc. (NASDAQ: TSRO) from 2016 until its acquisition by GlaxoSmithKline in 2019; and as a director, member of the Compensation Committee, and Chair of the Nominating and Corporate Governance Committee of Intelligent Medicine Acquisition Corp (NASDAQ: IQMD) from November 2021 to April 2023. Dr. Patel received her undergraduate degree from the University of Texas at Austin, her Master of Public Health from the University of California at Los Angeles and her medical degree from the University of Texas Health Science Center.
- Daniel G. Anderson
-
DanielG.Anderson是Sigilon的联合创始人，自2016年以来一直担任我们的董事会成员。Anderson博士是纳米治疗剂和生物材料领域的领先研究人员。他被任命在麻省理工学院（MIT）化学工程系、医学工程与科学研究所、科赫综合癌症研究所和哈佛-麻省理工学院（Harvard-MIT）健康科学与技术部任职。Anderson博士在加州大学圣克鲁斯分校（University of California at Santa Cruz）获得数学与生物学学士学位，并在加州大学戴维斯分校（University of California at Davis）获得分子遗传学博士学位。Anderson博士的工作成果是发表了400多篇论文、专利和专利申请。这些进步带来了已经商业化或正在临床开发的产品，以及包括CRISPR Therapeutics AG、Living Proof公司、Verseau Therapeutics公司和Olivo Laboratories公司在内的制药、生物技术和消费产品领域的公司的成立。
Daniel G. Anderson is a co-founder of Sigilon and has served as a member of our board of directors since 2016. Dr. Anderson is a leading researcher in the field of nanotherapeutics and biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. Dr. Anderson received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. Dr. Anderson's work has resulted in the publication of over 400 papers, patents and patent applications. These advances have led to products that have been commercialized or are in clinical development, as well as to the foundation of companies in the pharmaceutical, biotechnology and consumer product spaces including CRISPR Therapeutics AG, Living Proof, Inc., Verseau Therapeutics, Inc. and Olivo Laboratories, LLC. - DanielG.Anderson是Sigilon的联合创始人，自2016年以来一直担任我们的董事会成员。Anderson博士是纳米治疗剂和生物材料领域的领先研究人员。他被任命在麻省理工学院（MIT）化学工程系、医学工程与科学研究所、科赫综合癌症研究所和哈佛-麻省理工学院（Harvard-MIT）健康科学与技术部任职。Anderson博士在加州大学圣克鲁斯分校（University of California at Santa Cruz）获得数学与生物学学士学位，并在加州大学戴维斯分校（University of California at Davis）获得分子遗传学博士学位。Anderson博士的工作成果是发表了400多篇论文、专利和专利申请。这些进步带来了已经商业化或正在临床开发的产品，以及包括CRISPR Therapeutics AG、Living Proof公司、Verseau Therapeutics公司和Olivo Laboratories公司在内的制药、生物技术和消费产品领域的公司的成立。
- Daniel G. Anderson is a co-founder of Sigilon and has served as a member of our board of directors since 2016. Dr. Anderson is a leading researcher in the field of nanotherapeutics and biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. Dr. Anderson received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. Dr. Anderson's work has resulted in the publication of over 400 papers, patents and patent applications. These advances have led to products that have been commercialized or are in clinical development, as well as to the foundation of companies in the pharmaceutical, biotechnology and consumer product spaces including CRISPR Therapeutics AG, Living Proof, Inc., Verseau Therapeutics, Inc. and Olivo Laboratories, LLC.
- John Cox
-
John Cox自2019年以来一直担任我们的董事会成员。考克斯自2019年以来一直担任Repertoire Immune Medicines的首席执行官，曾于2017年至2019年担任赛诺菲（BioverativInc.）的首席执行官，此前，考克斯曾担任赛诺菲（Sanofi S.A.）的执行Vice President，2016年至2017年，他在BiogenInc.全球商业和技术运营，担任领导团队成员，负责全球110亿美元商业运营的所有方面，以及技术开发和所有药物供应。在此之前，他曾于2015年至2016年担任BiogenInc.制药运营与技术执行Vice President，负责监督该公司在全球的生产设施，供应链运营，技术开发，质量和工程。他也曾负责创立公司的生物仿制药业务，包括其在欧洲的成功商业化。Cox先生拥有密歇根大学（University of Michigan）的工商管理硕士学位，加利福尼亚州立大学（California State University）的细胞生物学硕士学位和亚利桑那州立大学（Arizona State University）的生物学学士学位。
John Cox has served as a member of our board of directors since 2019. Mr. Cox has served as the Chief Executive Officer of Repertoire Immune Medicines since 2019 and was formerly the Chief Executive Officer of Bioverativ Inc. from 2017 until 2019 which he built, grew, and led to a successful acquisition by Sanofi S.A. Previously, Mr. Cox was Executive Vice President, Global Commercial & Technical Operations at Biogen Inc. from 2016 until 2017 where he was a member of the leadership team and was globally responsible for all aspects of an $11 billion commercial operation, as well as technical development and all drug supply. Prior to that he served as Executive Vice President of Pharmaceutical Operations & Technology at Biogen Inc. from 2015 until 2016 in which capacity he oversaw the company's production facilities, supply chain operations, technical development, quality and engineering across the globe. He also had responsibility for the creation of the company's biosimilar business, including its successful commercialization in Europe. Mr. Cox holds an M.B.A. from the University of Michigan, an M.S. in cell biology from California State University and a B.S. in biology from Arizona State University. - John Cox自2019年以来一直担任我们的董事会成员。考克斯自2019年以来一直担任Repertoire Immune Medicines的首席执行官，曾于2017年至2019年担任赛诺菲（BioverativInc.）的首席执行官，此前，考克斯曾担任赛诺菲（Sanofi S.A.）的执行Vice President，2016年至2017年，他在BiogenInc.全球商业和技术运营，担任领导团队成员，负责全球110亿美元商业运营的所有方面，以及技术开发和所有药物供应。在此之前，他曾于2015年至2016年担任BiogenInc.制药运营与技术执行Vice President，负责监督该公司在全球的生产设施，供应链运营，技术开发，质量和工程。他也曾负责创立公司的生物仿制药业务，包括其在欧洲的成功商业化。Cox先生拥有密歇根大学（University of Michigan）的工商管理硕士学位，加利福尼亚州立大学（California State University）的细胞生物学硕士学位和亚利桑那州立大学（Arizona State University）的生物学学士学位。
- John Cox has served as a member of our board of directors since 2019. Mr. Cox has served as the Chief Executive Officer of Repertoire Immune Medicines since 2019 and was formerly the Chief Executive Officer of Bioverativ Inc. from 2017 until 2019 which he built, grew, and led to a successful acquisition by Sanofi S.A. Previously, Mr. Cox was Executive Vice President, Global Commercial & Technical Operations at Biogen Inc. from 2016 until 2017 where he was a member of the leadership team and was globally responsible for all aspects of an $11 billion commercial operation, as well as technical development and all drug supply. Prior to that he served as Executive Vice President of Pharmaceutical Operations & Technology at Biogen Inc. from 2015 until 2016 in which capacity he oversaw the company's production facilities, supply chain operations, technical development, quality and engineering across the globe. He also had responsibility for the creation of the company's biosimilar business, including its successful commercialization in Europe. Mr. Cox holds an M.B.A. from the University of Michigan, an M.S. in cell biology from California State University and a B.S. in biology from Arizona State University.
- Robert Langer
-
暂无中文简介
Robert Langer has served as a member of our board of directors since 2016. Since 2005 Dr. Langer has served as a David H. Koch Institute Professor at the Massachusetts Institute of Technology. Dr. Langer has served on the boards of directors of Abpro Corporation since 2016 Frequency Therapeutics, Inc. since 2016 Rubius Therapeutics, Inc. since 2014 Moderna, Inc. since 2010 and Lyra Therapeutics, Inc. since 2006. Dr. Langer has previously served on the boards of directors of Puretech Health plc, Momenta Pharmaceuticals, Inc., Wyeth Pharmaceuticals, Kala Pharmaceuticals, Inc., Fibrocell Science, Inc., and Millipore Corp. Dr. Langer holds a Sc.D. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Chemical Engineering from Cornell University. -
暂无中文简介
- Robert Langer has served as a member of our board of directors since 2016. Since 2005 Dr. Langer has served as a David H. Koch Institute Professor at the Massachusetts Institute of Technology. Dr. Langer has served on the boards of directors of Abpro Corporation since 2016 Frequency Therapeutics, Inc. since 2016 Rubius Therapeutics, Inc. since 2014 Moderna, Inc. since 2010 and Lyra Therapeutics, Inc. since 2006. Dr. Langer has previously served on the boards of directors of Puretech Health plc, Momenta Pharmaceuticals, Inc., Wyeth Pharmaceuticals, Kala Pharmaceuticals, Inc., Fibrocell Science, Inc., and Millipore Corp. Dr. Langer holds a Sc.D. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Chemical Engineering from Cornell University.
- Robert Ruffolo, Jr.
-
Robert Ruffolo，Jr.自2016年以来一直担任我们的董事会成员。从2000年到2008年，他曾担任Wyeth Pharmaceuticals的研究与开发总裁和企业高级副总裁。在这些职位上，他管理着一个由9000名科学家组成的研发组织，年度预算超过30亿美元。从2000年到2002年，他曾担任Wyeth Pharmaceuticals公司的执行Vice President，在那里他负责制药研究与开发。在加入Wyeth Pharmaceuticals之前，Ruffolo博士曾在SmithKline Beecham Pharmaceuticals plc（现为GlaxoSmithKline plc）工作了17年，1984年至2000年担任该公司的高级副总裁和全球生物科学总监。在加入SmithKline Beecham Pharmaceuticals plc之前，Ruffolo博士从1978年到1984年在礼来公司工作了6年，在那里他是一名高级药理学家。Ruffolo博士目前在AridisPharmaceuticals，Inc.、Diffusion Pharmaceuticals，Inc.和几家私营公司的董事会任职。他在俄亥俄州立大学（Ohio State University）获得药学学士学位，在俄亥俄州立大学（Ohio State University）获得药理学博士学位。
Robert Ruffolo, Jr. has served as a member of our board of directors since 2016. He served as the President of Research and Development and as the Corporate Senior Vice President of Wyeth Pharmaceuticals from 2000 through 2008. In these roles, he managed an R&D organization of 9000 scientists with an annual budget in excess of $3 billion. From 2000 to 2002 he served as an Executive Vice President at Wyeth Pharmaceuticals, where he was responsible for Pharmaceutical Research and Development. Prior to joining Wyeth Pharmaceuticals, Dr. Ruffolo spent 17 years at SmithKline Beecham Pharmaceuticals plc now GlaxoSmithKline plc where he was Senior Vice President and Director of Biological Sciences, Worldwide from 1984 to 2000. Before joining SmithKline Beecham Pharmaceuticals plc, Dr. Ruffolo spent six years at Eli Lilly and Company from 1978 to 1984 where he was a Senior Pharmacologist. Dr. Ruffolo currently serves on the boards of directors of Aridis Pharmaceuticals, Inc., Diffusion Pharmaceuticals, Inc. and several private companies. He received his B.S. in Pharmacy from The Ohio State University and his Ph.D. in Pharmacology from The Ohio State University. - Robert Ruffolo，Jr.自2016年以来一直担任我们的董事会成员。从2000年到2008年，他曾担任Wyeth Pharmaceuticals的研究与开发总裁和企业高级副总裁。在这些职位上，他管理着一个由9000名科学家组成的研发组织，年度预算超过30亿美元。从2000年到2002年，他曾担任Wyeth Pharmaceuticals公司的执行Vice President，在那里他负责制药研究与开发。在加入Wyeth Pharmaceuticals之前，Ruffolo博士曾在SmithKline Beecham Pharmaceuticals plc（现为GlaxoSmithKline plc）工作了17年，1984年至2000年担任该公司的高级副总裁和全球生物科学总监。在加入SmithKline Beecham Pharmaceuticals plc之前，Ruffolo博士从1978年到1984年在礼来公司工作了6年，在那里他是一名高级药理学家。Ruffolo博士目前在AridisPharmaceuticals，Inc.、Diffusion Pharmaceuticals，Inc.和几家私营公司的董事会任职。他在俄亥俄州立大学（Ohio State University）获得药学学士学位，在俄亥俄州立大学（Ohio State University）获得药理学博士学位。
- Robert Ruffolo, Jr. has served as a member of our board of directors since 2016. He served as the President of Research and Development and as the Corporate Senior Vice President of Wyeth Pharmaceuticals from 2000 through 2008. In these roles, he managed an R&D organization of 9000 scientists with an annual budget in excess of $3 billion. From 2000 to 2002 he served as an Executive Vice President at Wyeth Pharmaceuticals, where he was responsible for Pharmaceutical Research and Development. Prior to joining Wyeth Pharmaceuticals, Dr. Ruffolo spent 17 years at SmithKline Beecham Pharmaceuticals plc now GlaxoSmithKline plc where he was Senior Vice President and Director of Biological Sciences, Worldwide from 1984 to 2000. Before joining SmithKline Beecham Pharmaceuticals plc, Dr. Ruffolo spent six years at Eli Lilly and Company from 1978 to 1984 where he was a Senior Pharmacologist. Dr. Ruffolo currently serves on the boards of directors of Aridis Pharmaceuticals, Inc., Diffusion Pharmaceuticals, Inc. and several private companies. He received his B.S. in Pharmacy from The Ohio State University and his Ph.D. in Pharmacology from The Ohio State University.
- Eric Shaff
-
Eric Shaff自2017年以来一直担任我们的董事会成员。Shaff先生是赛里斯治疗公司的总裁兼首席执行官，自2015年起，他在赛里斯治疗公司担任了一系列领导职务。在赛里斯治疗公司之前，Shaff先生曾在MomentaPharmaceuticals，Inc.和健赞公司工作，在那里他担任Genzyme罕见遗传病部门的全球财务主管，此外还担任企业发展和企业财务方面的职务。Shaff先生还曾在辉瑞公司从事公司财务工作，并在Broadview International LLC（现Jefferies Broadview）从事投资银行业务。Shaff先生在宾夕法尼亚大学（University of Pennsylvania）获得文学学士学位，并在康奈尔大学（Cornell University）约翰逊管理研究生院（Johnson Graduate School of Management）获得工商管理硕士学位。
Eric Shaff has served as a member of our board of directors since 2017. Mr. Shaff is President and Chief Executive Officer of Seres Therapeutics, Inc., a role that follows a series of leadership positions at Seres Therapeutics, Inc. beginning in 2015. Prior to Seres Therapeutics, Inc., Mr. Shaff worked at Momenta Pharmaceuticals, Inc. and Genzyme Corporation, where he served as global head of finance of Genzyme's Rare Genetic Disease Division in addition to roles in corporate development and corporate Finance. Mr. Shaff has also worked in corporate finance at Pfizer Inc. and in investment banking with Broadview International LLC now Jefferies Broadview. Mr. Shaff earned a B.A. from the University of Pennsylvania and holds an M.B.A. from the Johnson Graduate School of Management at Cornell University. - Eric Shaff自2017年以来一直担任我们的董事会成员。Shaff先生是赛里斯治疗公司的总裁兼首席执行官，自2015年起，他在赛里斯治疗公司担任了一系列领导职务。在赛里斯治疗公司之前，Shaff先生曾在MomentaPharmaceuticals，Inc.和健赞公司工作，在那里他担任Genzyme罕见遗传病部门的全球财务主管，此外还担任企业发展和企业财务方面的职务。Shaff先生还曾在辉瑞公司从事公司财务工作，并在Broadview International LLC（现Jefferies Broadview）从事投资银行业务。Shaff先生在宾夕法尼亚大学（University of Pennsylvania）获得文学学士学位，并在康奈尔大学（Cornell University）约翰逊管理研究生院（Johnson Graduate School of Management）获得工商管理硕士学位。
- Eric Shaff has served as a member of our board of directors since 2017. Mr. Shaff is President and Chief Executive Officer of Seres Therapeutics, Inc., a role that follows a series of leadership positions at Seres Therapeutics, Inc. beginning in 2015. Prior to Seres Therapeutics, Inc., Mr. Shaff worked at Momenta Pharmaceuticals, Inc. and Genzyme Corporation, where he served as global head of finance of Genzyme's Rare Genetic Disease Division in addition to roles in corporate development and corporate Finance. Mr. Shaff has also worked in corporate finance at Pfizer Inc. and in investment banking with Broadview International LLC now Jefferies Broadview. Mr. Shaff earned a B.A. from the University of Pennsylvania and holds an M.B.A. from the Johnson Graduate School of Management at Cornell University.
- Douglas Cole
-
Douglas Cole, 他是医学博士。自2015年5月起担任Denali Therapeutics Inc.的董事会成员。他担任Sana Biotechnology, Inc.的董事（2006年8月以来）。他于2001年加入Flagship Ventures公司，在那里他目前担任普通合伙人。加入Flagship公司之前，他曾担任Vertex Pharmaceuticals公司（生物技术公司）的项目执行官、Cytotherapeutics公司（现称为StemCells公司，生物制药公司）的医药董事，以及Ensemble Therapeutics公司（生物制药公司）的首席执行官。他目前任职于9家私人公司的董事会，即Agios Pharmaceuticals公司、Concert Pharmaceuticals公司、Ensemble Therapeutics公司、Receptos公司、Quanterix公司、Selecta Biosciences公司、Avedro公司、 Permeon Biologics公司、Syros Pharmaceuticals公司。他持有达特茅斯学院（Dartmouth College）的英语学士学位（以优异成绩获得），以及the University of Pennsylvania School of Medicine的医学博士学位。
Douglas Cole has served as a member of our Board since April 2020. Dr. Cole joined Flagship Pioneering, which conceives, creates, resources and develops first-in-category life sciences companies, in 2001 and is currently a Managing Partner focused on life science investments. Dr. Cole currently serves on the board of directors of Denali Therapeutics, Foghorn Therapeutics, Sigilon Therapeutics and a number of private companies. In the past five years, Dr. Cole served on the boards of directors of Quanterix Corporation and Editas Medicine. Dr. Cole received his M.D. from the University of Pennsylvania School of Medicine and his B.A. in English from Dartmouth College. - Douglas Cole, 他是医学博士。自2015年5月起担任Denali Therapeutics Inc.的董事会成员。他担任Sana Biotechnology, Inc.的董事（2006年8月以来）。他于2001年加入Flagship Ventures公司，在那里他目前担任普通合伙人。加入Flagship公司之前，他曾担任Vertex Pharmaceuticals公司（生物技术公司）的项目执行官、Cytotherapeutics公司（现称为StemCells公司，生物制药公司）的医药董事，以及Ensemble Therapeutics公司（生物制药公司）的首席执行官。他目前任职于9家私人公司的董事会，即Agios Pharmaceuticals公司、Concert Pharmaceuticals公司、Ensemble Therapeutics公司、Receptos公司、Quanterix公司、Selecta Biosciences公司、Avedro公司、 Permeon Biologics公司、Syros Pharmaceuticals公司。他持有达特茅斯学院（Dartmouth College）的英语学士学位（以优异成绩获得），以及the University of Pennsylvania School of Medicine的医学博士学位。
- Douglas Cole has served as a member of our Board since April 2020. Dr. Cole joined Flagship Pioneering, which conceives, creates, resources and develops first-in-category life sciences companies, in 2001 and is currently a Managing Partner focused on life science investments. Dr. Cole currently serves on the board of directors of Denali Therapeutics, Foghorn Therapeutics, Sigilon Therapeutics and a number of private companies. In the past five years, Dr. Cole served on the boards of directors of Quanterix Corporation and Editas Medicine. Dr. Cole received his M.D. from the University of Pennsylvania School of Medicine and his B.A. in English from Dartmouth College.
- Rogerio Vivaldi Coelho
-
Rogerio Vivaldi Coelho自2018年起一直担任Sigilon Therapeutics，Inc.股份有限公司总裁兼首席执行官，并担任Sigillon Therapeutics，Inc.股份有限公司董事会成员。在加入Sigilon之前，Vivaldi博士自2016年起担任Bioverativ Inc.执行副总裁兼首席全球治疗官，直到2018年被赛诺菲收购，并于2014年至2016年间担任Spark Therapeutics首席商务官。在此之前，他在Genzyme任职20年期间，担任罕见病业务和肾脏与内分泌集团总裁，以及Genzyme拉丁美洲集团高级副总裁兼总经理，领导Genzyme的罕见病业务。维瓦尔迪博士拥有里约热内卢大学的医学学位。他在里约热内卢埃斯塔多大学完成了内分泌住院治疗，并在纽约西奈山医院中心完成了遗传学研究，重点研究戈谢病。维瓦尔迪博士拥有里约热内卢联邦大学COPPEAD的工商管理硕士学位。
Rogerio Vivaldi Coelho has served as Sigilon Therapeutics, Inc. President and Chief Executive Officer and as a member of Sigilon Therapeutics, Inc. board of directors since 2018. Prior to joining Sigilon, Dr. Vivaldi served as Executive Vice President and Chief Global Therapeutics Officer at Bioverativ Inc. from 2016 until it was acquired by Sanofi in 2018 and served as Chief Commercial Officer at Spark Therapeutics between 2014 and 2016. Before that he led Genzyme's rare disease business as President of both the rare disease business and the renal & endocrine group, as well as Senior Vice President and General Manager of Genzyme's Latin America Group during his 20-year tenure at Genzyme. Dr. Vivaldi holds his medical degree from the Universidade do Rio de Janeiro. He completed a residency in endocrinology at the Universidade do Estado do Rio de Janeiro and a fellowship at Mount Sinai Hospital Center in New York in the department of genetics, focusing on Gaucher disease. Dr. Vivaldi holds an M.B.A. degree from COPPEAD, Universidade Federal do Rio de Janeiro. - Rogerio Vivaldi Coelho自2018年起一直担任Sigilon Therapeutics，Inc.股份有限公司总裁兼首席执行官，并担任Sigillon Therapeutics，Inc.股份有限公司董事会成员。在加入Sigilon之前，Vivaldi博士自2016年起担任Bioverativ Inc.执行副总裁兼首席全球治疗官，直到2018年被赛诺菲收购，并于2014年至2016年间担任Spark Therapeutics首席商务官。在此之前，他在Genzyme任职20年期间，担任罕见病业务和肾脏与内分泌集团总裁，以及Genzyme拉丁美洲集团高级副总裁兼总经理，领导Genzyme的罕见病业务。维瓦尔迪博士拥有里约热内卢大学的医学学位。他在里约热内卢埃斯塔多大学完成了内分泌住院治疗，并在纽约西奈山医院中心完成了遗传学研究，重点研究戈谢病。维瓦尔迪博士拥有里约热内卢联邦大学COPPEAD的工商管理硕士学位。
- Rogerio Vivaldi Coelho has served as Sigilon Therapeutics, Inc. President and Chief Executive Officer and as a member of Sigilon Therapeutics, Inc. board of directors since 2018. Prior to joining Sigilon, Dr. Vivaldi served as Executive Vice President and Chief Global Therapeutics Officer at Bioverativ Inc. from 2016 until it was acquired by Sanofi in 2018 and served as Chief Commercial Officer at Spark Therapeutics between 2014 and 2016. Before that he led Genzyme's rare disease business as President of both the rare disease business and the renal & endocrine group, as well as Senior Vice President and General Manager of Genzyme's Latin America Group during his 20-year tenure at Genzyme. Dr. Vivaldi holds his medical degree from the Universidade do Rio de Janeiro. He completed a residency in endocrinology at the Universidade do Estado do Rio de Janeiro and a fellowship at Mount Sinai Hospital Center in New York in the department of genetics, focusing on Gaucher disease. Dr. Vivaldi holds an M.B.A. degree from COPPEAD, Universidade Federal do Rio de Janeiro.
- Robert Langer
-
Robert Langer，自2005年起担任麻省理工学院教授，在此之前，自1977年起担任麻省理工学院教授。从1995年到2002年，他担任美国食品和药物管理局科学委员会成员，包括四年的主席。他是美国国家科学院、美国国家工程院和美国国家医学院的当选成员。
Robert Langer,has been an Institute Professor at the Massachusetts Institute of Technology (MIT) since 2005, and has been a Professor at MIT since 1977. Dr. Langer served as a member of the Science Board to the U.S. Food and Drug Administration from 1995 to 2002, including as chairman for four years. He is an elected member of the National Academy of Sciences, the National Academy of Engineering, the National Academy of Medicine and the National Academy of Inventors. Dr. Langer has written over 1,550 articles and also has 1,450 issued or pending patents worldwide. Dr. Langer's patents have been licensed or sublicensed to over 400 pharmaceutical, chemical, biotechnology and medical device companies. B.S. in chemical engineering from Cornell University .Sc.D. in chemical engineering from the Massachusetts Institute of Technology. - Robert Langer，自2005年起担任麻省理工学院教授，在此之前，自1977年起担任麻省理工学院教授。从1995年到2002年，他担任美国食品和药物管理局科学委员会成员，包括四年的主席。他是美国国家科学院、美国国家工程院和美国国家医学院的当选成员。
- Robert Langer,has been an Institute Professor at the Massachusetts Institute of Technology (MIT) since 2005, and has been a Professor at MIT since 1977. Dr. Langer served as a member of the Science Board to the U.S. Food and Drug Administration from 1995 to 2002, including as chairman for four years. He is an elected member of the National Academy of Sciences, the National Academy of Engineering, the National Academy of Medicine and the National Academy of Inventors. Dr. Langer has written over 1,550 articles and also has 1,450 issued or pending patents worldwide. Dr. Langer's patents have been licensed or sublicensed to over 400 pharmaceutical, chemical, biotechnology and medical device companies. B.S. in chemical engineering from Cornell University .Sc.D. in chemical engineering from the Massachusetts Institute of Technology.
高管简历
中英对照 | 中文 | 英文- Deya Corzo
Deya Corzo，同出一辙担任负责医疗事务的副总裁（2014年4月以来），并于2015年7月被提拔为高级副总裁、肝/新陈代谢的治疗区域负责人。加入我们之前，她曾领导Genzyme公司的医疗团队，涉及Myozyme（酶替代治疗筛疾病）的全球开发和推出、Lumizyme （酶替代治疗筛疾病）的BLA提交和获得美国批准。她的医学事务经验包括担任美国和全球职务，负责两个非常成功的肿瘤药物：Velcade （Millennium/Takeda开发的治疗血液癌症的第一类蛋白酶体抑制剂）、Abraxane （Celgene公司商业化治疗血液癌症的紫杉醇的创新配方）。她获得儿科和临床遗传学认证。她是Harvard Medical School的儿科讲师，以及波士顿儿童医院遗传学诊所（the Children''s Hospital Genetics Clinic）的一个活跃的执业医师。
Deya Corzo has served as Sigilon Therapeutics, Inc.'s Chief Medical Officer since 2018. Previously, Dr. Corzo served as Chief Medical Officer of Sojournix Inc., from 2017 until 2018 where she led a team responsible for IND/CTA regulatory filings in the United States and the United Kingdom, the execution of their first-in-human clinical trials in those geographies, and for building up the company's clinical development group. Dr. Corzo previously served as SVP of R&D and Therapeutic Area Head for liver-amenable gene therapies at uniQure N.V. from 2014 until 2017 as Executive Medical Director at Celgene from 2012 until 2014 and various positions at Sanofi Genzyme from 2001 until 2008. Dr. Corzo is a faculty member of Harvard Medical School and a board-certified attending physician in Clinical Genetics at Boston Children's Hospital. She completed a residency in Pediatrics at Maimonides Medical Center in Brooklyn, NY, a clinical fellowship in Genetics at Boston Children's Hospital and a research fellowship in Immunogenetics at the Dana-Farber Cancer Institute. Dr. Corzo received her medical degree with a cum laude distinction from the Universidad Industrial de Santander in her native Colombia.- Deya Corzo，同出一辙担任负责医疗事务的副总裁（2014年4月以来），并于2015年7月被提拔为高级副总裁、肝/新陈代谢的治疗区域负责人。加入我们之前，她曾领导Genzyme公司的医疗团队，涉及Myozyme（酶替代治疗筛疾病）的全球开发和推出、Lumizyme （酶替代治疗筛疾病）的BLA提交和获得美国批准。她的医学事务经验包括担任美国和全球职务，负责两个非常成功的肿瘤药物：Velcade （Millennium/Takeda开发的治疗血液癌症的第一类蛋白酶体抑制剂）、Abraxane （Celgene公司商业化治疗血液癌症的紫杉醇的创新配方）。她获得儿科和临床遗传学认证。她是Harvard Medical School的儿科讲师，以及波士顿儿童医院遗传学诊所（the Children''s Hospital Genetics Clinic）的一个活跃的执业医师。
- Deya Corzo has served as Sigilon Therapeutics, Inc.'s Chief Medical Officer since 2018. Previously, Dr. Corzo served as Chief Medical Officer of Sojournix Inc., from 2017 until 2018 where she led a team responsible for IND/CTA regulatory filings in the United States and the United Kingdom, the execution of their first-in-human clinical trials in those geographies, and for building up the company's clinical development group. Dr. Corzo previously served as SVP of R&D and Therapeutic Area Head for liver-amenable gene therapies at uniQure N.V. from 2014 until 2017 as Executive Medical Director at Celgene from 2012 until 2014 and various positions at Sanofi Genzyme from 2001 until 2008. Dr. Corzo is a faculty member of Harvard Medical School and a board-certified attending physician in Clinical Genetics at Boston Children's Hospital. She completed a residency in Pediatrics at Maimonides Medical Center in Brooklyn, NY, a clinical fellowship in Genetics at Boston Children's Hospital and a research fellowship in Immunogenetics at the Dana-Farber Cancer Institute. Dr. Corzo received her medical degree with a cum laude distinction from the Universidad Industrial de Santander in her native Colombia.
- Glenn Reicin
Glenn Reicin自2019年以来一直担任我们的首席财务官。从2013年到2019年，Reicin先生担任Greyrock Biomedical Advisors，Ltd.的总裁，该公司为梦百合领域的公司提供一系列交易采购，估值，尽职调查和管理咨询服务。Reicin先生目前在Amplitude Healthcare Acquisition Corporation公司董事会任职，该公司是一家公共专业收购公司。此前，他曾担任Covidien plc的常驻执行官，以及Skyline Ventures Management LLC的董事总经理。任职Skyline Ventures Management LLC期间，他曾担任多家生物技术公司的活跃董事会成员，其中包括Novasys Medical Inc.（女性尿失禁微创治疗制造商）、SI-Bone Inc.（骶髂关节疾病微创手术治疗开发商）、Spinal Motion，Inc.，一种人工椎间盘植入物的开发商，用来保持被治疗的身体脊椎段的运动。Reicin先生在摩根士丹利担任多个职责递增的职位，他在摩根士丹利担任董事总经理，领导他们的梦百合股票研究团队。他的职业生涯始于摩根士丹利，在那里他成为涵盖医疗技术的股票研究的董事总经理。他的卖方职业生涯跨越18年，其中担任排名前三的分析师15年，连续6年位居榜首。Reicin先生拥有哈佛商学院（Harvard Business School）的工商管理硕士学位和布兰迪斯大学（Brandeis University）的工商管理硕士学位。
Glenn Reicin has served as our Chief Financial Officer since 2019. From 2013 until 2019 Mr. Reicin served as President of Greyrock Biomedical Advisors, Ltd., which provides a range of deal sourcing, valuation, due diligence and management consulting services for companies in the healthcare space. Mr. Reicin currently serves on the board of directors of Amplitude Healthcare Acquisition Corporation, a public specialty purpose acquisition company. Previously, he served as an Executive-in-Resident at Covidien Plc and Managing Director at Skyline Ventures Management LLC. At Skyline Ventures Management LLC, he served as an active board member at a number of biotech firms, including Novasys Medical Inc., a maker of minimally invasive treatments for female incontinence, SI-Bone Inc., a developer of a minimally invasive surgical treatment for sacroiliac joint disorders, and Spinal Motion, Inc., a developer of artificial disc implants to preserve motion at the treated spinal segment of the body. Mr. Reicin held various position of increasing responsibility at Morgan Stanley where he served as a Managing Director at Morgan Stanley where he headed their Healthcare Equity Research team. He started his career at Morgan Stanley where he became a Managing Director in equity research covering medical technology. His sell-side career spanned 18 years, including 15 years as a top-three ranked analyst and six consecutive years in the top spot. Mr. Reicin holds an M.B.A. from Harvard Business School and a B.A. from Brandeis University.- Glenn Reicin自2019年以来一直担任我们的首席财务官。从2013年到2019年，Reicin先生担任Greyrock Biomedical Advisors，Ltd.的总裁，该公司为梦百合领域的公司提供一系列交易采购，估值，尽职调查和管理咨询服务。Reicin先生目前在Amplitude Healthcare Acquisition Corporation公司董事会任职，该公司是一家公共专业收购公司。此前，他曾担任Covidien plc的常驻执行官，以及Skyline Ventures Management LLC的董事总经理。任职Skyline Ventures Management LLC期间，他曾担任多家生物技术公司的活跃董事会成员，其中包括Novasys Medical Inc.（女性尿失禁微创治疗制造商）、SI-Bone Inc.（骶髂关节疾病微创手术治疗开发商）、Spinal Motion，Inc.，一种人工椎间盘植入物的开发商，用来保持被治疗的身体脊椎段的运动。Reicin先生在摩根士丹利担任多个职责递增的职位，他在摩根士丹利担任董事总经理，领导他们的梦百合股票研究团队。他的职业生涯始于摩根士丹利，在那里他成为涵盖医疗技术的股票研究的董事总经理。他的卖方职业生涯跨越18年，其中担任排名前三的分析师15年，连续6年位居榜首。Reicin先生拥有哈佛商学院（Harvard Business School）的工商管理硕士学位和布兰迪斯大学（Brandeis University）的工商管理硕士学位。
- Glenn Reicin has served as our Chief Financial Officer since 2019. From 2013 until 2019 Mr. Reicin served as President of Greyrock Biomedical Advisors, Ltd., which provides a range of deal sourcing, valuation, due diligence and management consulting services for companies in the healthcare space. Mr. Reicin currently serves on the board of directors of Amplitude Healthcare Acquisition Corporation, a public specialty purpose acquisition company. Previously, he served as an Executive-in-Resident at Covidien Plc and Managing Director at Skyline Ventures Management LLC. At Skyline Ventures Management LLC, he served as an active board member at a number of biotech firms, including Novasys Medical Inc., a maker of minimally invasive treatments for female incontinence, SI-Bone Inc., a developer of a minimally invasive surgical treatment for sacroiliac joint disorders, and Spinal Motion, Inc., a developer of artificial disc implants to preserve motion at the treated spinal segment of the body. Mr. Reicin held various position of increasing responsibility at Morgan Stanley where he served as a Managing Director at Morgan Stanley where he headed their Healthcare Equity Research team. He started his career at Morgan Stanley where he became a Managing Director in equity research covering medical technology. His sell-side career spanned 18 years, including 15 years as a top-three ranked analyst and six consecutive years in the top spot. Mr. Reicin holds an M.B.A. from Harvard Business School and a B.A. from Brandeis University.
- Devyn Smith
Devyn Smith自2017年以来一直担任我们的首席运营官。在加入Sigilon之前，史密斯博士于2009年至2017年在辉瑞公司担任越来越重要的职务，包括辉瑞医药科学研发部门的业务运营和战略主管。他在该职位上的职责包括监督该部门的日常业务运营和制定可实施的战略。在加入辉瑞公司之前，史密斯博士是管理咨询公司The Frankel Group LLC的负责人。Smith博士在哈佛医学院（Harvard Medical School）获得遗传学博士学位，他的研究最终在《细胞，自然》（Cell，Nature）和《发展》（Development）等领先期刊上发表了12篇文章。他还持有Idaho State University生物学硕士学位和Brigham Young University动物学学士学位。
Devyn Smith has served as our Chief Operating Officer since 2017. Prior to joining Sigilon, Dr. Smith served in roles of increasing responsibility at Pfizer Inc. from 2009 until 2017 including Head of Business Operations & Strategy for Pfizer's Medicinal Sciences Division of R&D. His responsibilities in this position included oversight of both the day-to-day business operations of the division and the development of implementable strategies. Before his time at Pfizer Inc., Dr. Smith was a principal for The Frankel Group LLC, a management consulting firm. Dr. Smith received his Ph.D. in Genetics from Harvard Medical School where his research culminated in 12 publications in leading journals such as Cell, Nature, and Development. He also holds an M.S. in Biology from Idaho State University and a B.S. in Zoology from Brigham Young University.- Devyn Smith自2017年以来一直担任我们的首席运营官。在加入Sigilon之前，史密斯博士于2009年至2017年在辉瑞公司担任越来越重要的职务，包括辉瑞医药科学研发部门的业务运营和战略主管。他在该职位上的职责包括监督该部门的日常业务运营和制定可实施的战略。在加入辉瑞公司之前，史密斯博士是管理咨询公司The Frankel Group LLC的负责人。Smith博士在哈佛医学院（Harvard Medical School）获得遗传学博士学位，他的研究最终在《细胞，自然》（Cell，Nature）和《发展》（Development）等领先期刊上发表了12篇文章。他还持有Idaho State University生物学硕士学位和Brigham Young University动物学学士学位。
- Devyn Smith has served as our Chief Operating Officer since 2017. Prior to joining Sigilon, Dr. Smith served in roles of increasing responsibility at Pfizer Inc. from 2009 until 2017 including Head of Business Operations & Strategy for Pfizer's Medicinal Sciences Division of R&D. His responsibilities in this position included oversight of both the day-to-day business operations of the division and the development of implementable strategies. Before his time at Pfizer Inc., Dr. Smith was a principal for The Frankel Group LLC, a management consulting firm. Dr. Smith received his Ph.D. in Genetics from Harvard Medical School where his research culminated in 12 publications in leading journals such as Cell, Nature, and Development. He also holds an M.S. in Biology from Idaho State University and a B.S. in Zoology from Brigham Young University.
- Rogerio Vivaldi Coelho
Rogerio Vivaldi Coelho自2018年起一直担任Sigilon Therapeutics，Inc.股份有限公司总裁兼首席执行官，并担任Sigillon Therapeutics，Inc.股份有限公司董事会成员。在加入Sigilon之前，Vivaldi博士自2016年起担任Bioverativ Inc.执行副总裁兼首席全球治疗官，直到2018年被赛诺菲收购，并于2014年至2016年间担任Spark Therapeutics首席商务官。在此之前，他在Genzyme任职20年期间，担任罕见病业务和肾脏与内分泌集团总裁，以及Genzyme拉丁美洲集团高级副总裁兼总经理，领导Genzyme的罕见病业务。维瓦尔迪博士拥有里约热内卢大学的医学学位。他在里约热内卢埃斯塔多大学完成了内分泌住院治疗，并在纽约西奈山医院中心完成了遗传学研究，重点研究戈谢病。维瓦尔迪博士拥有里约热内卢联邦大学COPPEAD的工商管理硕士学位。
Rogerio Vivaldi Coelho has served as Sigilon Therapeutics, Inc. President and Chief Executive Officer and as a member of Sigilon Therapeutics, Inc. board of directors since 2018. Prior to joining Sigilon, Dr. Vivaldi served as Executive Vice President and Chief Global Therapeutics Officer at Bioverativ Inc. from 2016 until it was acquired by Sanofi in 2018 and served as Chief Commercial Officer at Spark Therapeutics between 2014 and 2016. Before that he led Genzyme's rare disease business as President of both the rare disease business and the renal & endocrine group, as well as Senior Vice President and General Manager of Genzyme's Latin America Group during his 20-year tenure at Genzyme. Dr. Vivaldi holds his medical degree from the Universidade do Rio de Janeiro. He completed a residency in endocrinology at the Universidade do Estado do Rio de Janeiro and a fellowship at Mount Sinai Hospital Center in New York in the department of genetics, focusing on Gaucher disease. Dr. Vivaldi holds an M.B.A. degree from COPPEAD, Universidade Federal do Rio de Janeiro.- Rogerio Vivaldi Coelho自2018年起一直担任Sigilon Therapeutics，Inc.股份有限公司总裁兼首席执行官，并担任Sigillon Therapeutics，Inc.股份有限公司董事会成员。在加入Sigilon之前，Vivaldi博士自2016年起担任Bioverativ Inc.执行副总裁兼首席全球治疗官，直到2018年被赛诺菲收购，并于2014年至2016年间担任Spark Therapeutics首席商务官。在此之前，他在Genzyme任职20年期间，担任罕见病业务和肾脏与内分泌集团总裁，以及Genzyme拉丁美洲集团高级副总裁兼总经理，领导Genzyme的罕见病业务。维瓦尔迪博士拥有里约热内卢大学的医学学位。他在里约热内卢埃斯塔多大学完成了内分泌住院治疗，并在纽约西奈山医院中心完成了遗传学研究，重点研究戈谢病。维瓦尔迪博士拥有里约热内卢联邦大学COPPEAD的工商管理硕士学位。
- Rogerio Vivaldi Coelho has served as Sigilon Therapeutics, Inc. President and Chief Executive Officer and as a member of Sigilon Therapeutics, Inc. board of directors since 2018. Prior to joining Sigilon, Dr. Vivaldi served as Executive Vice President and Chief Global Therapeutics Officer at Bioverativ Inc. from 2016 until it was acquired by Sanofi in 2018 and served as Chief Commercial Officer at Spark Therapeutics between 2014 and 2016. Before that he led Genzyme's rare disease business as President of both the rare disease business and the renal & endocrine group, as well as Senior Vice President and General Manager of Genzyme's Latin America Group during his 20-year tenure at Genzyme. Dr. Vivaldi holds his medical degree from the Universidade do Rio de Janeiro. He completed a residency in endocrinology at the Universidade do Estado do Rio de Janeiro and a fellowship at Mount Sinai Hospital Center in New York in the department of genetics, focusing on Gaucher disease. Dr. Vivaldi holds an M.B.A. degree from COPPEAD, Universidade Federal do Rio de Janeiro.